Evaluasi Ketaatan Penggunaan Antihipertensi di Apotek X _ Yogyakarta Periode Tahun 2009 Berdasarkan Parameter Medication Possession Ratio

  • RITA SUHADI UNIVERSITAS SANATA DHARMA

Abstrak

World Health Organization melaporkan hipertensi sebagai global health risk nomor satu pada tahun 2009. Ketaatan penggunaan obat antihipertensi akan menurunkan berbagai risiko penyakit kardiovaskuler. Telah dilakukan penelitian cross-sectional untuk mengamati profil penggunaan antihipertensi dan mengevaluasi ketaatan pasien berdasarkan jenis kelamin, program bantuan pembiayaan, dan tunggal atau kombinasi, serta profil ketaatan pasien berupa Medication Possession Ratio (MPR) di Apotek X Yogyakarta tahun 2009. Objek yang diteliti adalah peresepan antihipertensi dari pasien langgangan dengan peresepan antihipertensi minimal 3 kali kunjungan. Parameter MPR dihitung sebagai rasio jumlah hari pasien mendapat obat sampai resep terakhir dengan jumlah total hari pasien harusnya mendapat obat sampai resep terakhir yang ditebus. Dari hasil penelitian diperoleh golongan dan jenis obat antihipertensi yang paling sering diresepkan berdasarkan jumlah unit dan paling banyak rerata (mean) unit obat per resep, yaitu ACEI (captopril 25 mg), dan berdasarkan frekuensi peresepan adalah CCB (amlodipin 5mg). Penggunaan obat generik dalam unit, 5.6 kali dibandingkan obat bermerk, dalam frekuensi peresepan 3.2 kali lipat, dan dalam rerata unit per resep 1.7 kali lipat. Tidak ada perbedaan bermakna antara ketaatan pasien berdasarkan jenis kelamin, program bantuan pembiayaan, maupun antihipertensi tunggal atau kombinasi berdasarkan parameter MPR (p > 0.05); mean MPR adalah 0.78 ± 0.15 (0.41-1.00); dan sebanyak 50.000 memiliki MPR > 0.8.

Referensi

1. Setiati S and Sutrisna B. Prevalence of hypertension Without anti-hypertensive medications and its association with social demographic characteristics among 40 years and above adult population in Indonesia. Acta Med Indones-Indones J Intern Med. 2005. 37(1): 20-25.

2. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension, Clinical Review. 2001. 977-80.

3. WHO. Global health risks, mortality and burden of disease attributable to selected major risks. Geneva: WHO; 2009. 1-12,17.

4. Saseen JJ, MacLaughlin EJ. Hypertension in pharmacotherapy, a pathophysiologic approach.7th Ed, New York: Mc Graw Hill Co; 2008. 139-71.

5. Robertson TA, Cooke CE, Wang J S, Shaya FT, Lee HY. Effect of medication burden on persistent use of lipidlowering drugs among patients with hypertension. Am J Manag Care. 2008. 14(11):710-16.

6. McWilliams JM, Meara E, Zaslavsky AM, Ayanlan JZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: US trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med. 2009. 150:505-15.

7 . Yoon J., Ettner SL.,C0st-sharing and adherence to antihypertensives for low and high adherers, Am J Manag Care. 2009. 15(11):833-40.

8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 1220 JL, et al. The seventh report of the Joint National Committee on prevention, detection,
evaluation, and treatment of high blood pressure. the JNC7 Report in JAMA. 2003. 289(19):2560-72.
Diterbitkan
2011-04-30
##submission.howToCite##
SUHADI, RITA. Evaluasi Ketaatan Penggunaan Antihipertensi di Apotek X _ Yogyakarta Periode Tahun 2009 Berdasarkan Parameter Medication Possession Ratio. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 9, n. 1, p. 53-59, apr. 2011. ISSN 2614-6495. Tersedia pada: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/327>. Tanggal Akses: 16 sep. 2025
##submission.howToCite.citationFormats##
Terbitan
Vol 9 No 1 (2011): JIFI
Bagian
Articles
##submission.license##

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.